ArticleInfection and drug resistance2020
Three Years of Evaluation to Determine Reduction of Antibiotic Resistance in Gram-Negative Bacteria by the Saudi National Action Plan.
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Antibacterial mechanism and in vivo efficacy of cladribine against carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2026Article
- Antibiotic resistance among Gram-negative bacteria in bloodstream infections in Shiraz, Iran (2012-2023).AMB Express · 2026Article
- Evaluating the effects of temperature and agitation on biofilm formation of bacterial pathogens isolated from raw cow milk.BMC microbiology · 2024Article
- The emergence of highly resistant and hypervirulent Klebsiella pneumoniae CC14 clone in a tertiary hospital over 8 years.Genome medicine · 2024Article
- Evaluation to Determine Antibiotic Resistance Reduction in Gram-Negative Bacteria from 2019 to 2021 by the Saudi Arabia National Plan.Journal of pharmacy & bioallied sciences · 2024Article
- Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistantAnnals of medicine · 2022Article
- Silver Nanoparticle-Based Combinations with Antimicrobial Agents against Antimicrobial-Resistant Clinical Isolates.Antibiotics (Basel, Switzerland) · 2022Article
- Review
- ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacterial antibiotic resistance (AR) is a primary public health concern. In 2017, the Saudi National Action Plan (SNAP) implemented several strategies to overcome AR. Here, to better understand the effectiveness of that plan, we evaluated the rates of AR, extended-spectrum beta-lactamase (ESBL) positivity, and multi-drug resistance (MDR) among gram-negative bacteria in a private Saudi hospital.
methodsThis retrospective study included all patients with a confirmed diagnosis of gram-negative bacterial infection from January 2017 to December 2019. Identification of bacterial strains was performed using VITEK 2 ID-GNB cards, while AR, ESBL, and MDR were determined using AST-No. 12 cards, both used as recommended by the manufacturer. Cards were loaded into a VITEK 2 system for examination.
resultsA total of 4760 isolated gram-negative bacteria were collected. The most isolated organism was
conclusionOur findings revealed that the rates of AR, ESBL, and MDR reduced over time, which suggests the SNAP is effective at overcoming AR risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.